Total position of
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of the issuer |
Resulting situation on the date on which threshold was crossed or reached | 10.85% | 0% | 10.85% | 20,336,858 |
Position of previous notification (if applicable) |
|
|
|
|
Notified details of the resulting situation on the date on which the threshold was crossed:
| Number of shares and voting rights | % of shares and voting rights | ||
Class/type of shares | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) |
FI4000480454 | 2,206,370 | 0 | 10.85% | 0% |
SUBTOTAL | 2,206,370 | 10.85% |
After
Further enquiries
Certified adviser
Bioretec in brief
Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
Bioretec is developing the new RemeOs(TM) product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs(TM) implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their
Better healing - Better life. www.bioretec.com
https://news.cision.com/bioretec/r/notification-in-accordance-with-chapter-9--section-10-of-the-securities-market-act-on-a-change-in-ho,c3984635
(c) 2024 Cision. All rights reserved., source